Sunshine Biopharma Files Draft Information Statement
Bitget2026/10/14 21:22- Sunshine Biopharma's draft information statement outlines shareholder authorization for discounted share issuance exceeding 20% of outstanding common stock.
- The October 13, 2026, authorization covers Series D Warrant exercise-price adjustments and proportional underlying share adjustments following share combinations.
- Share-combination adjustments could lower the initial $0.66 exercise price to a minimum of $0.275, increasing shares issuable proportionately.
- Shareholders also authorized voluntary reductions in Series D Warrant exercise prices at the board's discretion.
- The warrants were issued in an offering that closed October 9, 2026, raising approximately $6 million in gross proceeds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

Why Nintendo Stock Is One to Watch Ahead of the Holiday Season

A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.

Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.